« Back to Record
Sternberg, C. N., Dumez, H., Van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabro, F., Collette, L., Lacombe, D., & EORTC Genitourinary Tract Cancer Group, (2009). Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of oncology, 20(7), 1264-1269. doi:10.1093/annonc/mdn784
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/119812



